CLL
Haematology · 2008–2025
31decisions
9medicines
20carried consumer input
175individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| acalabrutinib Previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in combination with venetoclax as a fixed duration regimen. | Nov 2025 | Recommended with restriction | input received Lymphoma Australia · Rare Cancers Australia |
| acalabrutinib Treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), as monotherapy or in combination with… | Jul 2023 | Recommended | input received Rare Cancers Australia |
| acalabrutinib Relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (rrCLL/SLL). This submission sought to amend the risk-sharing arrangement… | Mar 2023 | Not recommended | none received |
| acalabrutinib Treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who are considered unsuitable for… | Dec 2022 | Not recommended | 15 individuals |
| ibrutinib Treatment of previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in combination with venetoclax in patients considered… | Dec 2022 | Not recommended | 16 individuals Lymphoma Australia · Leukaemia Foundation |
| venetoclax Previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) in patients with coexisting conditions who are inappropriate for… | Jul 2020 | Recommended with restriction | 13 individuals |
| acalabrutinib Previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients considered unsuitable for treatment with a purine… | Jul 2020 | Not recommended | 13 individuals |
| acalabrutinib Treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who are considered unsuitable for… | Mar 2020 | Recommended with restriction | 9 individuals Lymphoma Australia · Leukaemia Foundation · Rare Cancers Australia |
| venetoclax Previously untreated chronic lymphocytic leukaemia (CLL) in patients with coexisting conditions who are inappropriate for fludarabine-based… | Mar 2020 | Not recommended | 8 individuals Leukaemia Foundation · Lymphoma Australia · Rare Cancers Australia |
| ibrutinib First-line treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in patients with deletion 17p (del17p). | Nov 2019 | Recommended with restriction | 8 individuals |
| obinutuzumab Treatment of chronic lymphocytic leukaemia (CLL) in previously untreated patients with comorbidities who are inappropriate for fludarabine-based… | Jul 2018 | Recommended with restriction | none received |
| venetoclax Treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who are unsuitable for treatment or retreatment with a purine analogue,… | Nov 2018 | Recommended | 1 individuals |
| venetoclax Relapsed or refractory chronic lymphocytic leukaemia (CLL) in patients with 17p deletion and patients with highly refractory disease. | Jul 2017 | Recommended with restriction | 2 individuals |
| rituximab Treatment of CD20 positive chronic lymphocytic leukaemia (CLL) in combination with chemotherapy. | Mar 2017 | Recommended with restriction | none received |
| venetoclax Relapsed/refractory chronic lymphocytic leukaemia (CLL) in patients with 17p deletion/TP53 mutation and patients with highly refractory disease. | Mar 2017 | Deferred | 40 individuals |
| ibrutinib First-line treatment of chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) in previously untreated unfit patients unsuitable for… | Nov 2017 | Not recommended | 4 individuals |
| venetoclax Treatment of relapsed or refractory chronic lymphocytic leukaemia (R/R CLL) in patients who have failed a kinase inhibitor. | Nov 2017 | Recommended with restriction | input received Lymphoma Australia |
| idelalisib Relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) in patients who are unfit for chemo-immunotherapy, in… | Jul 2016 | Recommended with restriction | none received |
| ibrutinib Second-line therapy in patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) deemed unfit for further treatment with a purine… | Mar 2016 | Deferred | input received |
| idelalisib Treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in combination with rituximab in patients… | Mar 2016 | Deferred | none received |
| ibrutinib Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) that is relapsed or refractory to at least one prior therapy, in patients considered… | Nov 2016 | Recommended | none received |
| ibrutinib Treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in patients who have received at least one prior… | Jul 2015 | Not recommended | 29 individuals |
| idelalisib Second-line treatment of chronic lymphocytic leukaemia (CLL) in patients for whom chemo-immunotherapy is not considered suitable, upon relapse after at least… | Mar 2015 | Not recommended | 5 individuals |
| obinutuzumab Treatment of chronic lymphocytic leukaemia (CLL) in previously untreated, unfit elderly patients with comorbidities, used in combination with chlorambucil. | Mar 2015 | Recommended with restriction | 6 individuals |
| idelalisib Second-line treatment of chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) that is relapsed or refractory after at least one prior… | Nov 2015 | Not recommended | 6 individuals |
| obinutuzumab Treatment of chronic lymphocytic leukaemia (CLL) in previously untreated patients with CD20 positive CLL and comorbidities (CIRS score >6, or creatinine… | Jul 2014 | Not recommended | input received Lymphoma Australia · Medical Oncology Group · Haematology Society |
| ofatumumab Treatment of previously untreated CD20 positive chronic lymphocytic leukaemia (CLL) in combination with chlorambucil, for patients inappropriate for… | Nov 2014 | Recommended | none received |
| rituximab Treatment of CD20 positive, chronic lymphocytic leukaemia, in combination with chemotherapy. | Mar 2010 | Recommended | no section in document |
| rituximab CD20 positive, chronic lymphocytic leukaemia, in combination with chemotherapy. The TGA-registered indication is for first-line treatment of patients with CD20… | Nov 2010 | Recommended with restriction | no section in document |
| fludarabine phosphate Treatment of B-cell chronic lymphocytic leukaemia (CLL) in combination with cyclophosphamide in patients with advanced disease (Binet Stage B or C) or evidence… | Mar 2008 | Recommended with restriction | no section in document |
| pegfilgrastim Primary prophylaxis of neutropenia in patients with chronic lymphocytic leukaemia (CLL) being treated with fludarabine and cyclophosphamide (FC), and secondary… | Nov 2008 | Recommended with restriction | no section in document |
Who spoke
Lymphoma Australia · Rare Cancers Australia · Leukaemia Foundation · Medical Oncology Group · Haematology Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 20 of 27 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.